Skip to Content
Merck
All Photos(1)

Documents

1269447

USP

Fenofibrate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H21ClO4
CAS Number:
49562-28-9
Molecular Weight:
360.83
MDL number:
MFCD00133314
UNSPSC Code:
41116107
PubChem Substance ID:
329749836
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fenofibrate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

InChI key

YMTINGFKWWXKFG-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fenofibrate Capsules
  • Fenofibrate Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

Fenofibrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

Fenofibrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1269618

Fenofibrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

F0048035

Fenofibrate impurity G, European Pharmacopoeia (EP) Reference Standard

1133558

Choline Fenofibrate, United States Pharmacopeia (USP) Reference Standard

PHR2864

Fenofibrate Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H373

Precautionary Statements

P260 - P314 - P501

Hazard Classifications

STOT RE 2 Oral

Target Organs

Liver

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Fenofibric acid analytical standard

Supelco

90568

Fenofibric acid

Bezafibrate ≥98%, solid

Sigma-Aldrich

B7273

Bezafibrate

Rafael Simó et al.
Current medicinal chemistry, 20(26), 3258-3266 (2013-06-12)
Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage
Jonathan E Noonan et al.
Diabetes, 62(12), 3968-3975 (2013-11-23)
The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications. This interest stems from two recent large, well-designed clinical trials that demonstrated large reductions in the progression of DR
Michel P Hermans
Diabetes & vascular disease research, 8(3), 180-189 (2011-05-18)
Microvascular complications are common in type 2 diabetes in primary care. Intensified management of glycaemia or blood pressure had little effect on microvascular complication rates in recent large trials (ADVANCE, VADT, ACCORD). In 2005, the FIELD study demonstrated a significant
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service